The Evans Foundation for Molecular Medicine, established in 2006, promotes research into Multiple Systems Atrophy and seeks to make information on the disease, research progress, and patient care available to people living with MSA and their caregivers.

Our Scientific Advisory Board continually reviews current research pertaining to MSA, including the formation of clinical trials, grant proposals, and FDA applications for innovative pharmaceuticals, which may hold promise for addressing the symptoms, discovering the cause, and developing a cure of this severe and rapidly progressing neurological condition.

The Board interprets this research and makes it understandable and accessible to the general MSA community, through its website, support group meetings and chat sites, conventions and community networks. The information gained from such communications can positively impact the lives of people living with MSA, and potentially improve their quality of life.

Ultimately, The Evans Foundation works to direct funding into research which offers the potential for managing the symptoms, slowing the progression and/or eventually contributing to finding a cure for this rare and debilitating disease.

Dr. Glen Evans

Our founder, Dr. Glen Evans, passed away on Sept 6th, 2010 after living for five years with MSA.

A major figure in the sequencing of the human genome and the development of synthetic biology, Dr. Evans was the first graduate of UCSD's then-new M.D.-Ph.D. program. He co-founded the DNA-chip company Nanogen in San Diego—later to become a major NASDAQ-listed biotech company—which was based on his patents, and spent several years directing the sequencing of the human genome first at the Salk Institute in San Diego, and then at the University of Texas Southwestern Medical Center.

In 2000, Dr. Evans founded Egea Biosciences, one of the first companies to use synthetic biology to create novel pharmaceuticals and improve existing treatments for a wide range of diseases. Noted for its work on improving drugs like the anti-anemia agent erythropoietin and for work with the US Army to create blood-clotting bandages, Egea was acquired in 2004 by Centocor, a division of Johnson & Johnson.

In 2005, Dr. Evans was diagnosed with Multiple Systems Atrophy. In response, he founded the Evans Foundation for Molecular Medicine, along with his sister Dr. Joyce Evans and nephew Constantine Evans, in order to support research into his illness and education on research and care for others suffering from the disease.